Trethera Technology

Why TRE-515 Matters. A New Frontier.

Trethera’s first-in-class drug, TRE-515, is leading the way by focusing on the salvage pathway – a key metabolic process essential for the growth of diseased cells in cancers, autoimmune diseases, and inflammatory disorders.

Illustration of a DNA strand inside of a pill.

Illustration of a virus cell colored blue.

What is the Salvage Pathway?

The salvage pathway supports the rapid growth of abnormal cells by supplying materials for faster cell division. The salvage pathway is upregulated by abnormal cells in diseases like cancer, MS, lupus, and Crohn’s but is less active in healthy adult cells. By blocking abnormal cell division, TRE-515 may impact multiple diseases with fewer side effects.

Revolutionary Approach

Salvage Pathway and dCK Activation in Diseases

The de novo and salvage pathways create deoxyribonucleoside triphosphates (dNTPs) for DNA replication. Deoxycytidine kinase (dCK) is the rate-limiting enzyme in the salvage pathway. In cases of rapid and aberrant cell proliferation, such as cancer and autoimmune diseases, the salvage pathway and dCK are activated.

Illustration of deoxyribonucleoside salvate pathway

The History of Trethera & TRE-515

Blocking dCK in the salvage pathway builds on over a decade of research discoveries.

UCLA (2009-2020)